Absence of detectable EWS/FLI1 expression after therapy-induced neural differentiation in Ewing sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Ewing sarcoma and peripheral primitive neuroectodermal tumors (pPNETs) originate from neural crest cells and exhibit limited neural differentiation.
• Most pPNETs are characterized by specific chromosomal translocations, such as t(11;22) or t(21;22), resulting in gene fusions like EWS/FLI1 or EWS/ERG.
• These gene fusions produce chimeric oncoproteins that function as aberrant transcription factors, but their precise role in tumor differentiation is not fully understood.

Observation:

• A 10-year-old girl presented with a forearm Ewing sarcoma expressing EWS/FLI1 fusion transcripts.
• Following treatment with surgery, chemotherapy, and radiation, residual tumor was detected.
• The residual tumor exhibited well-differentiated peripheral neural features and lacked detectable EWS/FLI1 expression, with clonal relation to the primary tumor.

Findings:

• The study presents a case of Ewing sarcoma where the residual tumor showed significant neural differentiation after therapy.
• Crucially, the residual, differentiated tumor lacked detectable expression of the EWS/FLI1 fusion transcript.
• This observation suggests a potential link between the absence of EWS/FLI1 and the acquisition of neural differentiation.

Implications:

• The findings provide presumptive evidence that EWS/FLI1 oncoproteins may actively inhibit neural differentiation in Ewing sarcoma cells.
• Therapeutic strategies targeting or downregulating EWS/FLI1 could potentially promote tumor differentiation.
• Further research is warranted to elucidate the mechanisms by which EWS/FLI1 influences differentiation and to explore its therapeutic potential.